Skip to content

Agios Pharmaceuticals

US · AGIO #2841 by market cap Listed 1970
27.60 -1.16 -4.03%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 1.93 Expensive vs history 79th percentile
5-year average 1.66 · #230 of 514 in Biotechnology
P/E ratio -5.01 In line with history 48th percentile
5-year average -3.38 · forward -8.27
P/S ratio 13.41 Cheap vs history 10th percentile
5-year average 136.55 · forward 6.18 · #192 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Agios Pharmaceuticals (AGIO) 1.65B -4.37 1.69 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value35.77 Economic moatNone UncertaintyVery High

Trading 29.6% below Morningstar's fair value estimate.

Fair value

Agios Pharmaceuticals Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 12% discount to our quantitative fair value estimate of $35.77 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's solid growth strengthens our quantitative valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. Reflecting the firm's growth is its revenue 3-year growth of 83.0%, which sits in the top 10% compared with peers globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.

On a different note, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 8.1%, for example, sits in the bottom 10% compared with global peers. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Agios Pharmaceuticals discussion 0 comments

Add a comment